Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD 83.30
-2.15 (-2.52%)
Jun 26, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 3,761 employees as of December 31, 2025. The number of employees increased by 726 or 23.92% compared to the previous year.
Employees
3,761
Change (1Y)
726
Growth (1Y)
23.92%
Revenue / Employee
904.30K HKD
Profits / Employee
-329.32K HKD
Market Cap
76.73B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| Sichuan Kelun-Biotech Biopharmaceutical | 2,045 |
| RemeGen | 3,048 |
| Innovent Biologics | 7,502 |
| WuXi Biologics | 13,252 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
Akeso News
- 11 days ago - Akeso's Ligufalimab Combination Shows Deep Responses And Survival Benefit In Frontline AML - Nasdaq
- 11 days ago - Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 - PRNewsWire
- 16 days ago - Akeso's Gumokimab Gets NMPA Nod For Treating Plaque Psoriasis - Nasdaq
- 16 days ago - Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio - PRNewsWire
- 27 days ago - An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. - Market Watch
- 27 days ago - Akeso lung cancer drug shines in trials, boosting hopes in US$20b market - South China Morning Post
- 27 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 4 weeks ago - Akeso (AKESF) Reports Positive Phase 3 Results for Lung Cancer Treatment - GuruFocus